Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.62 |
| ▸ | CTSB | P07858 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.62 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 5/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256118 | 0.93 | CTSL (0.54) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL18596866 | 0.86 | CARM1 (0.58) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL18596737 | 0.86 | CARM1 (0.58) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL15800371 | 0.86 | CARM1 (0.58) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL14256113 | 0.85 | CTSL (0.48) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL16903412 | 0.84 | CHRM2 (0.47) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL16903411 | 0.84 | CHRM2 (0.47) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL14047773 | 0.83 | CHRM2 (0.71) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL11226439 | 0.83 | NAAA (0.45) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL11222724 | 0.83 | NAAA (0.60) | CTSLCTSBCTSKTMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4360464-A | Process for production of 1-aryloxy-aminopropane derivatives | TEIKOKU HORMONE MFG. CO. LTD. (JP) | 1982-11-23 | — | — | US | claimed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-4360464-A | Process for production of 1-aryloxy-aminopropane derivatives | TEIKOKU HORMONE MFG. CO. LTD. (JP) | 1982-11-23 | — | — | US | disclosed |
| US-4018824-A | ANTIULCER AND ADRENERGIC BLOCKING AGENTS | TEIKOKU HORMONE MFG. CO., LTD. (JA) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | CTSL 4628/4885CTSB 3378/4885CTSK 4259/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | CTSL 4716/4885CTSB 3940/4885CTSK 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.